A study to learn how well enfortumab vedotin (EV) with pembrolizumab works and how safe it is in people with advanced urothelial cancer: a plain language summary of the EV-302/KEYNOTE-A39 study
- Thomas Powles
- , Begoña P. Valderrama
- , Shilpa Gupta
- , Jens Bedke
- , Eiji Kikuchi
- , Jean Hoffman-Censits
- , Gopa Iyer
- , Christof Vulsteke
- , Se Hoon Park
- , Sang Joon Shin
- , Daniel Castellano
- , Giuseppe Fornarini
- , Jian Ri Li
- , Mahmut Gümüş
- , Nataliya Mar
- , Yohann Loriot
- , Aude Fléchon
- , Ignacio Duran
- , Alexandra Drakaki
- , Sujata Narayanan
- Queen Mary University of London
- Hospital Universitario Virgen del Rocio
- Cleveland Clinic Foundation
- Klinikum Stuttgart
- St. Marianna University School of Medicine
- Johns Hopkins University
- Memorial Sloan-Kettering Cancer Center
- AZ Maria Middelares
- University of Antwerp
- Yonsei University
- Hospital Universitario 12 de Octubre
- University Eye Clinic
- Veterans General Hospital-Taichung Taiwan
- Istanbul Medeniyet University
- University of California at Irvine
- Gustave Roussy
- Centre Léon Bérard
- Hospital Universitario Marques de Valdecilla
- University of California at Los Angeles
- Seagen Inc.
- Astellas Pharma Inc.
- Merck
- Netherlands Cancer Institute
Research output: Contribution to journal › Article › peer-review